




Non-small cell lung carcinoma (NSCLC)

Post-treatment assessment

Clinical summary – Patient 1

- 60 year-old smoker with right-sided lung carcinoma and contralateral mediastinal nodal metastases (N3 disease)
- Managed with chemoradiotherapy & restaged after 3 cycles

PET/CT findings



PET/CT scan shows partial metabolic response to treatment with a small amount of residual FDG avid disease in the primary tumour (axial slice) and lymph nodes (whole body MIP images)


Clinical summary – Patient 2

- Male 64 year-old with metastatic non-small cell lung carcinoma for restaging post-completion of neoadjuvant chemotherapy

PET/CT findings

Baseline PET/CT

Post-chemotherapy PET/CT



Post-therapy PET scan shows progressive metabolic disease to treatment

Teaching point

- FDG PET response DURING neoadjuvant chemotherapy or radiotherapy is potentially appropriate as tumours which respond poorly may benefit from a change in treatment dose or management.
- FDG PET response AFTER neoadjuvant chemotherapy can be used to select patients with stage III tumours for subsequent surgical resection.
- If metastatic mediastinal lymph nodes show good response to chemotherapy, debulking or curative surgery may be considered.

MacManus M, *et al.* Int J Radiat Oncol Biol Phys. 2008; 72:1298-1306